IRIS Institutional Research Information System - OPENBS Open Archive UniBS

RUSSO, DOMENICO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 28.214
AS - Asia 16.080
EU - Europa 11.833
SA - Sud America 3.426
Continente sconosciuto - Info sul continente non disponibili 1.118
AF - Africa 405
OC - Oceania 58
Totale 61.134
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 27.656
SG - Singapore 5.480
CN - Cina 5.212
BR - Brasile 2.830
UA - Ucraina 2.782
IT - Italia 2.043
HK - Hong Kong 1.827
DE - Germania 1.609
PL - Polonia 1.095
VN - Vietnam 1.076
FI - Finlandia 949
FR - Francia 782
BD - Bangladesh 619
GB - Regno Unito 615
TR - Turchia 592
RU - Federazione Russa 562
IE - Irlanda 498
IN - India 454
SE - Svezia 310
CA - Canada 269
AR - Argentina 228
MX - Messico 149
IQ - Iraq 132
ZA - Sudafrica 123
ID - Indonesia 106
JP - Giappone 100
NL - Olanda 99
EC - Ecuador 94
ES - Italia 85
CZ - Repubblica Ceca 78
CO - Colombia 75
AT - Austria 71
SA - Arabia Saudita 60
BE - Belgio 57
VE - Venezuela 57
UZ - Uzbekistan 56
AU - Australia 55
PK - Pakistan 48
MA - Marocco 46
EG - Egitto 40
PY - Paraguay 38
MU - Mauritius 35
CL - Cile 34
PE - Perù 34
JM - Giamaica 30
NG - Nigeria 30
AE - Emirati Arabi Uniti 28
JO - Giordania 28
KE - Kenya 28
EU - Europa 26
AZ - Azerbaigian 25
IL - Israele 25
DZ - Algeria 22
TN - Tunisia 22
UY - Uruguay 22
CH - Svizzera 21
PH - Filippine 20
LT - Lituania 19
KR - Corea 18
NP - Nepal 18
OM - Oman 18
DK - Danimarca 17
ET - Etiopia 17
TH - Thailandia 16
IR - Iran 15
MY - Malesia 15
PA - Panama 15
RO - Romania 15
SN - Senegal 15
KG - Kirghizistan 14
TT - Trinidad e Tobago 14
CR - Costa Rica 13
DO - Repubblica Dominicana 13
GR - Grecia 13
HN - Honduras 13
KZ - Kazakistan 12
PT - Portogallo 12
AL - Albania 11
BO - Bolivia 11
HU - Ungheria 11
LB - Libano 10
MD - Moldavia 10
PS - Palestinian Territory 10
BA - Bosnia-Erzegovina 9
BG - Bulgaria 9
SK - Slovacchia (Repubblica Slovacca) 9
NI - Nicaragua 8
LK - Sri Lanka 7
LV - Lettonia 7
SV - El Salvador 7
AM - Armenia 6
BB - Barbados 6
HR - Croazia 6
RS - Serbia 6
AO - Angola 5
BY - Bielorussia 5
NO - Norvegia 5
BH - Bahrain 4
CI - Costa d'Avorio 4
CU - Cuba 4
Totale 59.959
Salva come PNG Salva come JPEG
Città #
Singapore 2.809
Woodbridge 2.462
Fairfield 2.432
Ashburn 2.265
Jacksonville 1.976
Hong Kong 1.823
Houston 1.797
Ann Arbor 1.356
San Jose 1.135
Cambridge 1.085
Warsaw 1.075
Wilmington 974
The Dalles 968
Seattle 962
Princeton 935
Beijing 846
Chandler 800
New York 760
Nanjing 657
Council Bluffs 568
Los Angeles 504
Dublin 493
Helsinki 489
Lauterbourg 479
Istanbul 437
Dallas 388
Columbus 376
Ho Chi Minh City 355
Munich 334
Brescia 330
Des Moines 326
Milan 277
Nanchang 267
São Paulo 264
Shanghai 232
Hanoi 230
Buffalo 228
Moscow 192
Redondo Beach 177
Changsha 172
San Diego 171
Shenyang 166
San Francisco 153
Dearborn 148
Santa Clara 147
Tianjin 143
Jinan 133
Chicago 129
Hebei 129
Boardman 118
Orem 118
Jiaxing 109
Turku 108
London 101
Rome 98
Hangzhou 96
Tokyo 89
Brooklyn 87
Verona 81
Kunming 76
Toronto 75
Rio de Janeiro 71
Nuremberg 70
Denver 69
Frankfurt am Main 69
Phoenix 68
Atlanta 67
Chennai 66
Guangzhou 66
Kocaeli 65
Brasília 64
Johannesburg 60
Montreal 60
Brno 59
Zhengzhou 58
Belo Horizonte 57
Brussels 56
Curitiba 54
Pune 54
Boston 49
Ningbo 49
Romola 47
Tashkent 47
Baghdad 45
Stockholm 45
Lanzhou 44
Manchester 44
Mexico City 44
Haiphong 43
Poplar 41
Charlotte 38
Mumbai 37
Turin 37
Dong Ket 36
Norwalk 36
Da Nang 35
Amsterdam 34
Salvador 34
Jakarta 33
Campinas 31
Totale 38.692
Salva come PNG Salva come JPEG
Nome #
Mesenchymal stromal cells (MSCs) induce ex vivo proliferation and erythroid commitment of cord blood haematopoietic stem cells (CB-CD34+ cells) 328
BACTERIAL BLOOD STREAM INFECTIONS NEGATIVELY IMPACT ON OUTCOME OF PATIENTS TREATED WITH ALLOGENEIC STEM CELL TRANSPLANTATION: 6 YEARS SINGLE-CENTRE EXPERIENCE 297
Postremission sequential monitoring of minimal residual disease by WT1 Q-PCR and multiparametric flow cytometry assessment predicts relapse and may help to address risk-adapted therapy in acute myeloid leukemia patients 293
Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain 273
Circulating endothelial cell count: a reliable marker of endothelial damage in patients undergoing hematopoietic stem cell transplantation 271
A standardized flow cytometry network study for the assessment of circulating endothelial cell physiological ranges 271
“Variant-specific discrepancy when quantitating BCR-ABL1 e13a2 and e14a2 transcripts using the Europe Against Cancer qPCR assay.” Is dPCR the key? 257
Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. 243
Zebrafish disease models in hematology: Highlights on biological and translational impact 239
Do chromosomal abnormalities show up during mesenchymal stromal cell expansion? 236
3D gelatin-chitosan hybrid hydrogels combined with human platelet lysate highly support human mesenchymal stem cell proliferation and osteogenic differentiation 216
A specific Toll-like receptor profile on T lymphocytes and values of monocytes correlate with bacterial, fungal, and cytomegalovirus infections in the early period of allogeneic stem cell transplantation 212
Feasibility of tumor‑derived exosome enrichment in the onco‑hematology leukemic model of chronic myeloid leukemia 211
Bloodstream infections in haematological cancer patients colonized by multidrug-resistant bacteria 203
Comparative study on ATG-thymoglobulin versus ATG-fresenius for the graft-versus-host disease (GVHD) prophylaxis in allogeneic stem cell transplantation from matched unrelated donor: a single-centre experience over the contemporary years 200
Betaherpesvirus Reactivation and Toll-Like Receptor Expression After Allogeneic Stem Cell Transplantation. 194
Evaluation of Circulating Endothelial Cells as Direct Marker of Endothelial Damage in Allo-Transplant Recipients at High Risk of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome 192
Rational Design and Development of Anisotropic and Mechanically Strong Gelatin-Based Stress Relaxing Hydrogels for Osteogenic/Chondrogenic Differentiation 189
Targeting HRASV12G Expression to the Zebrafish Early Hemogenic Progenitors Induces a Myeloproliferative Disorder by Repressing the Notch Pathway. 189
EXPRESSION OF TOLL-LIKE RECEPTORS ON PERIPHERAL BLOOD CELLS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: ONGOING RESULTS OF A PROSPECTIVE STUDY. 188
Comparative Somatic Mutational Profiling of CD34+ Hematopoietic Precursors (HSC) and Circulating Endothelial Cells (CEC) in Patients with Primary Myelofibrosis (PMF) 187
A first update on mapping the human genetic architecture of COVID-19 186
Counting circulating endothelial cells in allo-HSCT: an ad hoc designed polychromatic flowcytometry-based panel versus the CellSearch System 186
A Gene Panel NGS-Based Strategy for Genomic Characterization of Acute Myeloid Leukemias (AMLs) 183
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease 181
Profile of Toll-Like Receptors on Peripheral Blood Cells in Relation to Acute Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation 179
Advances in CMV Management: A Single Center Real-Life Experience 178
Acute graft-versus-host disease and expression of Toll-like receptors on peripheral blood cells after allogeneic stem cell transplantation 176
TARGETING HRASV12G EXPRESSION TO THE ZEBRAFISH EARLY HEMOGENIC PROGENITORS INDUCES A MYELOPROLIFERATIVE DISORDER BY REPRESSING THE NOTCH PATHWAY. 173
Central Venous Catheter-Related Bloodstream Infection Caused by Brevibacterium casei in a Hematology Patient 173
Multidimensional Geriatric Assessment for Elderly Patients (≥60 years) Submitted for Allogeneic Stem Cell Transplantation. a French (Paris) - Italian (Brescia) 10-Years Experience on 228 Patients 172
Expression of Toll-Like Receptors on Peripheral Blood Cells After Allogeneic Stem Cell Transplantation: Results of a Prospective Study. 171
Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR) 170
SIRPB1 Is a Strong Predictor Biomarker of Response to 5-Azacitidine Therapy in MDS and AML Patients 169
CMV MANAGEMENT WITH SPECIFIC IMMUNOGLOBULINS: A MULTICENTRIC RETROSPECTIVE ANALYSIS ON 92 ALLOTRANSPLANTED PATIENTS 167
Development of BCR-ABL1 Transgenic Zebrafish Model Reproducing Chronic Myeloid Leukemia (CML) Like-Disease and Providing a New Insight into CML Mechanisms 167
Venetoclax plus decitabine as a bridge to allogeneic haematopoietic stem-cell transplantation in older patients with acute myeloid leukaemia (VEN-DEC GITMO): final report of a multicentre, single-arm, phase 2 trial 166
Clinical Care of Hematological Patients in a Bone Marrow Transplant Unit: Do Human Resources Influence Infection Incidence? 166
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients. 165
Chitosan-Hydrogel Polymeric Scaffold Acts as an Independent Primary Inducer of Osteogenic Differentiation in Human Mesenchymal Stromal Cells 165
In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants 163
Fungemia in hematological malignancies: SEIFEM-2015 survey 163
High risk-myelodysplastic syndrome following CAR T-cell therapy in a patient with relapsed diffuse large B cell lymphoma: A case report and literature review 162
Procoagulant cellular activity and disseminated intravascular coagulation in acute non-lymphoid leukaemia. 161
Intermittent Imatinib (INTERIM) Treatment of Patients with Ph+ Chronic Myeloid Leukemia in Complete Cytogenetic Response: Cytogenetic and Molecular Data At One Year. 161
Peripheral Blood WT1 Expression Predicts Relapse in AML Patients Undergoing Allogeneic Stem Cell Transplantation. 161
Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation 161
A prospective comparison of alpha-IFN and conventional chemotherapy in Ph+ chronic myeloid leukemia. Clinical and cytogenetic results at 2 years in 322 patients 160
Identification of a Novel Mutation Predisposing to Familial AML and MDS Syndrome By a NGS Approach 160
Central nervous system angiitis in Hodgkin's disease. 159
5-azacitidine five days/monthly schedule in symptomatic low-risk (IPSS: 0-1) myelodisplastic (MDS) patients. clinical and biological effects. 158
Bioengineered scaffolding for mandibular reconstruction: a preclinical, xenograft animal study 157
Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent 156
Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target? 156
MULTI-GENOTYPING OF MINOR HISTOCOMPATIBILITY ANTIGENS (MHAGS) IN ALLOGENEIC STEM CELL TRANSPLANTATION AND THEIR ROLE IN DETERMINING GRAFT VERSUS HOST DISEASE (GVHD) AND GRAFT VERSUS LEUKEMIA (GVL) EFFECT. 156
"Real-life' analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study 156
RT-qPCR versus Digital PCR: How Do They Impact Differently on Clinical Management of Chronic Myeloid Leukemia Patients? 156
Development of a Preclinical Double Model of Mandibular Irradiated Bone and Osteoradionecrosis in New Zealand Rabbits 155
Assessment of Liver Damage with Transient Hepatic Elastography (FIBROSCAN) in patients with chronic Graft-Versus-Host Disease. 155
PARAMETERS OF PROTEIN METABOLISM AND THYROID FUNCTION AS PREDICTORS OF A SCORING SYSTEM FOR ACUTE AND CHRONIC GRAFT-VERSUS-HOST DISEASE 154
Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment 154
Screening of Bcr-Abl transcripts in Philadelphia negative essential thrombocythemia. 153
Targeting oncogene expression to endothelial cells induces proliferation of the myelo-erythroid lineage by repressing the notch pathway. 153
Development of a cell culture model based on biocompatible polymeric scaffolds engineered with human Mesenchymal Stromal Cells (MSCs) for cartilage and bone regenerative therapy 153
P-glycoprotein (PGP) and lung resistance-related protein (LRP) expression and function in leukaemic blast cells. 152
Antilymphocyte globulin for prevention of chronic graft-versus-host disease 152
3D-MAPPING OF MESENCHYMAL STEM CELLS GROWTH ON BIOENGINEERED SCAFFOLDS FOR MAXILLOFACIAL SKELETON REGENERATION: A PRECLINICAL, IN VITRO STUDY 152
Is the New Tci Score Sufficient to Categorize the Intensity of Conditioning? a Single-Centre Study 150
Fludarabine-based induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients. 150
Baseline factors associated with response to ruxolitinib: An independent study on 408 patients with myelofibrosis 150
First Interim Report of the Italian Multicentric Phase-III Randomized Study to Optimize TKIs Multiple Approaches - (OPTkIMA) in Elderly Patients (older than 60 years) with Ph+ Chronic Myeloid Leukemia (CML) and MR3.0/ MR4.0 Stable Molecular Response 150
Single Cell Analysis of Circulating Endothelial Cells in Allogeneic Hematopoietic Stem Cell Transplant; To Whom Do They Belong: Host or Donor? 149
Bone marrow CD34+ molecular chimerism as an early predictor of relapse after allogeneic stem cell transplantation in patients with acute myeloid leukemia 147
SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia. 147
Concomitant ABCG2 overexpression and FLT3-ITD mutation identify a subset of acute myeloid leukemia patients at high risk of relapse 147
Impedance-based monitoring of mesenchymal stromal cell three-dimensional proliferation using aerosol jet printed sensors: A tissue engineering application 147
CT-290: Clinical Frailty Scale as a Novel Tool to Evaluate Patients’ Eligibility for Allogeneic Stem Cell Transplant: A Single-Center Experience on 234 Patients >50 Years Old 147
Procoagulant cellular activity and disseminated intravascular coagulation in acute non-lymphoid leukaemia 146
Bone Marrow Stroma and Vascular Contributions to Myeloma Bone Homing 146
ANTI-CMV Immunoglobulins in Association with ANTI-CMV Drugs in Patients with Hematological Malignancies Submitted to Allogeneic STEM CELL Transplantation: A MULTI-Center Retrospective Experience 146
Parameters of Protein Metabolism and Thyroid Function As Predictors in a Scoring System for Acute and Chronic Graft-Versus-Host Disease 145
Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia After Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey. 145
INTEGRATED CORE-SHELL BIOACTIVE STRUCTURE FOR THE REGENERATION OF BONE AND OSTEOCHONDRAL TISSUES 144
Hyperactive Akt1 Signaling Increases Tumor Progression and DNA Repair in Embryonal Rhabdomyosarcoma RD Line and Confers Susceptibility to Glycolysis and Mevalonate Pathway Inhibitors 143
Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP) 142
Advances in the treatment of monoclonal gammapathies: the emerging role of targeted therapy in plasma cell dyscrasias. 142
A NEW PROMISING APPROACH TO PERFORM HLA TYPING IN A QUICKLY, SIMPLE AND ACCURATE WAY: THE PYROSEQUENCING 142
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients. 141
Laboratory diagnostics of inherited platelet disorders. 141
Digital PCR (Dpcr) a Step Forward to Detection and Quantification of Minimal Residual Disease (MRD) in Ph+/BCR-ABL1 Chronic Myeloid Leukemia (CML) 141
TRIDIMENSIONAL BIOACTIVE POROUS BODY FOR BONE TISSUE REGENERATION AND PROCESS FOR ITS PREPARATION 141
Multidimensional geriatric assessment for elderly hematological patients (≥60 years) submitted to allogeneic stem cell transplantation. A French-Italian 10-year experience on 228 patients 140
Sensitivity of chronic myeloid leukemia hemopoietic progenitors to PTT-119 in combination with human recombinant interferon alpha and gamma 139
Laparoscopic splenectomy in the management of hematological diseases 139
Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-kit positive acute myeloid leukemia. Results of an italian multicentric phase II study. 139
Parameters of Protein Metabolism and Thyroid Function As Predictors in a Scoring System for Acute and Chronic Graft-Versus-Host Disease 139
Comparative Study on Fresenius-ATG Versus Thymoglobuline-ATG for the Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Stem Cell Transplantation from Matched Unrelated Donor: A Single Center Experience on 76 Patients 139
Successful hematopoietic stem cell transplantation for complete CTLA-4 haploinsufficiency due to a de novo monoallelic 2q33.2-2q33.3 deletion 138
Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients. 137
Long-term follow-up of the Italian trial of interferon- versus conventional chemotherapy in chronic myeloid leukemia 137
Totale 17.157
Salva come PNG Salva come JPEG
Categoria #
all - tutte 310.199
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 310.199
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20223.323 0 575 66 244 107 233 171 266 198 441 274 748
2022/20232.713 571 96 68 211 213 725 13 229 318 35 105 129
2023/20243.469 162 75 233 168 151 598 159 140 953 41 64 725
2024/20258.648 76 93 95 972 922 700 731 274 1.097 685 1.684 1.319
2025/202619.293 1.558 2.529 1.591 2.962 1.579 1.359 2.598 871 1.237 1.676 808 525
2026/20271.672 906 766 0 0 0 0 0 0 0 0 0 0
Totale 61.134